Ayça ALTINCIK, Pınar GENÇPINAR, Gönül ÇATLI, Ece BÖBER, Korcan DEMİR, Ayhan ABACI

Erken başlangıçlı Graves olgusu

Graves hastalığı, otoimmün bir hastalık olup, hipertiroidi ile seyreder ve çocukluk çağında nadir görülür. İki yaşında kız hasta, bir yıldır gözlerinin dışarıya doğru çıkık olması nedeniyle başvurdu. Fizik bakısında propitoz, taşikardi ve toraks sol ön duvarında, orta klavikular hatta, 6x4 cm çapında geniş bir adet hiperpigmente lekesi vardı. Olgunun tiroid işlev testlerinden ST4: 4,00 ng/dL (N: 0,8-1,9), ST3: 7,7 pg/mL (N: 1.57-4,71), TSH: 0,004 uIU/mL ( N: 0,4-5), anti-tiroglobülin:

Infantile Graves disease

Graves disease is an autoimmune disorder presenting with hyperthyroidism and the disease is rare in childhood. Two-year-old female patient was admitted to our clinic for her evident orbital puffiness. Physical examination revealed propitosis, tachycardia and a hyperpigmented spot with a diameter of 6x4 cm. on the skin of the left hemithorax. Evaluation of thyroid function tests showed the following values: fT4: 4.00 ng/dl (N: 0.8-1.9), fT3: 7,7 pg/ml (N: 1.57-4.71), TSH: 0.004 uIU/ml (N: 0.4-5), anti-thyroglobulin:

PDF

___

1.Dallas JS, Foley TP Hyperthyroidism. In: Lifshitz F (ed). Pediatric endocrinology. Fifth edition. Newyork: Marcel Dekker Inc, 2007: 415-42.
2.Wong GW, Cheng PS. Increasing incidence of childhood Graves disease in Hong Kong: a follow-up study. Clinical Endocrinol(Oxf) 2001: 54: 547-50.
3.Lavard L, Ranløv I, Perrild H, Andersen O, Jacobsen BB. Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study. Eur J Endocrinology 1994; 130: 565-8.
4.Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985; 60: 1019-24.
5.Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000; 85: 3678-82.
6.Kaguelidou F Carel JC, Léger J. Graves disease in childhood: advances in management with antithyroid drug therapy. Horm Res 2009; 71: 310-7.
7.Dattani M, Tziaferi V, Hindmarsh PC. Evaluation of disordered puberty. In: Brook C, Klayton P Brown R, (eds). Brook clinical pediatric endocrinology textbook. 6th ed. Hong Kong: 2009; 227.
8.Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis 2008; 3:12.
9.Uretsky SH, Kennerdell JS, Gutai JP Graves ophthalmopathy in childhood and adolescence. Arch Ophthalmol 1980; 98: 1963-4.
10.Grüters A. Ocular manifestations in children and adolescents with thyrotoxicosis. Exp Clin Endocrinol Diabetes 1999;107(Suppl 5): 172-4.
11.Goldstein SM, Katowitz WR, Moshang T, Katowitz JA. Pediatric thyroid-associated orbitopathy: the Childrens Hospital of Philadelphia experience and literature review. Thyroid 2008; 18: 997-9.
12.Chan W, Wong GW, Fan DS, Cheng AC, Lam DS, Ng JS. Ophthalmopathy in childhood Graves disease. Br J Ophthalmol 2002; 86: 740-2.
13.Krassas GE, Segni M, Wiersinga WM. Childhood Graves ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 2005; 153: 515-21.
14.Antoniazzi F Zamboni G, Cerini R, Lauriola S, DallAgnola A, Tatò L. Graves ophthalmopathy evolution studied by MRI during childhood and adolescence. J Pediatr 2004; 144: 527-31.
15.Acuna OM, Athannassaki I, Paysse EA. Association between thyroid-stimulating immunoglobulin levels and ocular findings in pediatric patients with Graves disease. Trans Am Ophthalmol Soc 2007; 105: 146-51.
16.Rivkees SA. Pediatric Graves disease: controversies in management. Horm Res Paediatr 2010; 74: 305-11.
17.Panamonta O, Sumethkul V, Radinahmed P Laopaiboon M, Kirdpon W. Propylthiouracil associated antineutrophil cytoplasmic antibodies (ANCA) in patients with childhood onset Graves disease. J Pediatr Endocrinol Metab 2008; 21: 539-43.
18.Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves patients ts. J Clin Endocrinol Metab 2004; 89: 4229-33.
19.Metso S, Jaatinen P Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab 2007; 92: 2190-6.
20.Kaguelidou F Alberti C, Castanet M, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008; 93: 3817-26.